The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor
about
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?
P2860
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor
@ast
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor
@en
type
label
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor
@ast
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor
@en
prefLabel
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor
@ast
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor
@en
P2093
P2860
P356
P1476
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor
@en
P2093
Creemers GJ
Gerrits CJ
Harteveld M
Planting AS
Pritchard JF
Schellens JH
de Boer-Dennert M
P2860
P2888
P304
P356
10.1038/BJC.1997.490
P407
P577
1997-01-01T00:00:00Z
P5875
P6179
1050881654